Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib.
Pascale Tomasini, Oscar Juan-Vidal, Raffaele Califano, Chien-Chung Lin, Pauline Hulo, Christophe Dooms, Jian Fang, Ana Blasco, Dariusz Kowalski, Jorge Salinas, Govind Babu, Tho Lye Mun, Alessandra Bearz, Veerle Surmont, Clarissa Baldotto, Richu Sharma, Oscar Arrieta, Katarzyna Stencel, Cynthia Card, Alona Zer, Erminia Massarelli, Bruno Fang, Sandeep Mashru, Julia Schuchard, Jan Sermon, Joris Diels, Pei-Ling Chu, Monica Withelder, Joshua M Bauml, Sujay Shah, Mahadi Baig, Enriqueta Felip
Clin Lung Cancer 27(2) 38-47
摘要
摘要
OBJECTIVE: The MARIPOSA-2 study demonstrated improved progression-free survival with amivantamab and chemotherapy compared with chemotherapy alone in patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (NSCLC) with disease progression on or after treatment with osimertinib. This publication describes the results of patient-reported outcomes (PROs) measures and time to symptomatic progression (TTSP) for 2 treatment arms. METHODS: PRO instruments included the European Organization for Research and Treatment of Cancer Quality of Life (QoL) Questionnaire Core 30 (EORTC QLQ-C30), Patient-Reported Outcomes Measurement Information System Physical Function Short Form 8c, and the NSCLC Symptom Assessment Questionnaire. Changes from baseline were analyzed using mixed-effects models for repeated measures. Treatment comparisons were based on least-squares means. The hazard ratio for TTSP was estimated using a stratified Cox regression model with P value derived from a stratified log-rank test. RESULTS: Patients received amivantamab-chemotherapy (n = 131) or chemotherapy alone (n = 263). PRO scores were stable over time with little or no group differences in least-squares mean change from baseline. At 6 months postbaseline, 55.1% of patients in the amivantamab-chemotherapy arm reported improved or stable EORTC QLQ-C30 global health status/QoL scores compared with 29.1% in the chemotherapy arm. TTSP was prolonged for the amivantamab-chemotherapy treatment group versus chemotherapy alone (hazard ratio [HR] [95% CI], 0.73 [0.55-0.96]; nominal P = .0259). CONCLUSION: PRO results indicate that the clinical benefits of adding amivantamab to chemotherapy were achieved without compromising health-related QoL. Amivantamab-chemotherapy prolonged TTSP versus chemotherapy alone.
KM 提取结果
0 个 Figure · 0 个 KM 面板